Filtered By:
Condition: Babies Heart Conditions
Management: Centers for Disease Control and Prevention (CDC)

This page shows you your search results in order of date.

Order by Relevance | Date

Total 12 results found since Jan 2013.

What Prohibition Can Teach Us About Drug and Alcohol Policy Today
It’s widely understood today that drinking while pregnant is harmful for the fetus. But the link between alcohol and the health of infants wasn’t as well known in the 1930s, when prohibition was repealed in the U.S. and all sorts of people, pregnant women included, began drinking again.Because prohibition was lifted on a piecemeal basis across the U.S., some counties continued to prohibit alcohol, or stay “dry,” while their neighboring counties were “wet.” Those conditions created what economists call a natural experiment, and made it possible to track the health impacts of maternal drin...
Source: TIME: Health - August 2, 2023 Category: Consumer Health News Authors: Oliver Staley Tags: Uncategorized Public Health Source Type: news

Stewardship for Science and Vaccines
Despite the success of vaccines in the modern world, including the rapid development of the COVID-19 vaccine, my state is now experiencing a large measles outbreak and a decline in immunization rates. At the turn of the century, the Centers for Disease Control and Prevention published “Ten Great Public Health Achievements” of the twentieth century in the United States.1 Vaccination topped the list, a national and global success story. Other achievements included improvements in motor-vehicle safety, control of infectious diseases, safer workplaces, decline in deaths from coro nary heart disease and stroke, safer and he...
Source: Pediatric Clinics of North America - February 24, 2023 Category: Pediatrics Authors: Tina L. Cheng Tags: Foreword Source Type: research

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need for data in ...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revascularization, a c...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Landmark Phase 3 VOYAGER PAD Study of XARELTO ® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefit using...
Source: Johnson and Johnson - March 28, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

For the First Time in Four Years, the U.S. Life Expectancy Rose a Little
(NEW YORK) — Life expectancy in the United States is up for the first time in four years. The increase is small — just a month — but marks at least a temporary halt to a downward trend. The rise is due to lower death rates for cancer and drug overdoses. “Let’s just hope it continues,” said Robert Anderson, who oversees the report released Thursday by the Centers for Disease Control and Prevention. The latest calculation is for 2018 and factors in current death trends and other issues. On average, an infant born that year is expected to live about 78 years and 8 months, the CDC said. For...
Source: TIME: Health - January 30, 2020 Category: Consumer Health News Authors: Associated Press Tags: Uncategorized health onetime overnight Source Type: news

7 Tips To Lower Diabetes Risk in Menopause During the Holidays
By now, most people have been to a holiday party or two. Lots of food, lots of eggnog and other carb laden alcoholic beverages, and lots of grazing all day long on all the boxes of candy friends and business acquaintances sent to us. It's easy to gain the five pounds most people gain during the holidays, and in the process, raise your blood sugar or glucose levels too high. That's your body letting you know you have prediabetes (higher than normal but still below diabetes levels) or diabetes, and unless you take action soon, your body won't like it. Diabetes silently sneaks up on you and if untreated, slowly weakens your ...
Source: Healthy Living - The Huffington Post - December 23, 2016 Category: Consumer Health News Source Type: news

South Carolina Is FED UP
When asked to speak for a group of third and fourth graders about making "healthy choices," I picked the topic that most children have in common ... sugar! I began our discussion with one simple question. "If your parents came into the room and saw you eating out of the sugar bowl, what would they say?" One young man stated it best. "Are you crazy? Put that spoon down!" "Why would your parents say that?" I asked. Another little girl could barely contain herself. Waving her hand furiously she blurted out, "Because all that sugar is bad for you!" Out of the mouths of babes. When I talk to children, teens or adults,...
Source: Healthy Living - The Huffington Post - September 17, 2015 Category: Consumer Health News Source Type: news

10 Good Reasons To Get A Flu Shot
By Melaina Juntti for Men's Journal How many times have you heard you should get a flu shot? There's good reason for the hype: Over the past few years, the influenza vaccine has prevented millions of flu cases and tens of thousands of related hospitalizations, according to Centers for Disease Control and Prevention. Although an increasing number of people are getting vaccinated every year, more than half of American men still aren't doing it, for a variety of reasons, most of which aren't backed by science. "Men have this macho sense that if they do get the flu, they can tough it out," says William Schaffner, M.D., chair...
Source: Healthy Living - The Huffington Post - November 29, 2014 Category: Consumer Health News Source Type: news